Next Article in Journal
Retrospective Proteomic Analysis of Cellular Immune Responses and Protective Correlates of p24 Vaccination in an HIV Elite Controller Using Antibody Arrays
Previous Article in Journal
Small-Molecule Inhibition of Rho/MKL/SRF Transcription in Prostate Cancer Cells: Modulation of Cell Cycle, ER Stress, and Metastasis Gene Networks
Previous Article in Special Issue
A Mismatch EndoNuclease Array-Based Methodology (MENA) for Identifying Known SNPs or Novel Point Mutations
Please note that, as of 18 July 2017, Microarrays has been renamed to High-Throughput and is now published here.
Open AccessReview

Advantages of Array-Based Technologies for Pre-Emptive Pharmacogenomics Testing

School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan 2308, Australia
The Bosch Institute and Discipline of Physiology, University of Sydney, Sydney 2006, Australia
Institute of Genetics and Cytology, School of Life Sciences, Northeast Normal University, Changchun 130024, China
Author to whom correspondence should be addressed.
Academic Editors: Yuriy Alekseyev and Gang Liu
Microarrays 2016, 5(2), 12;
Received: 29 February 2016 / Revised: 4 May 2016 / Accepted: 17 May 2016 / Published: 28 May 2016
(This article belongs to the Special Issue Microarrays in the Era of Next Generation Sequencing)
As recognised by the National Institutes of Health (NIH) Precision Medicine Initiative (PMI), microarray technology currently provides a rapid, inexpensive means of identifying large numbers of known genomic variants or gene transcripts in experimental and clinical settings. However new generation sequencing techniques are now being introduced in many clinical genetic contexts, particularly where novel mutations are involved. While these methods can be valuable for screening a restricted set of genes for known or novel mutations, implementation of whole genome sequencing in clinical practice continues to present challenges. Even very accurate high-throughput methods with small error rates can generate large numbers of false negative or false positive errors due to the high numbers of simultaneous readings. Additional validation is likely to be required for safe use of any such methods in clinical settings. Custom-designed arrays can offer advantages for screening for common, known mutations and, in this context, may currently be better suited for accredited, quality-controlled clinical genetic screening services, as illustrated by their successful application in several large-scale pre-emptive pharmacogenomics programs now underway. Excessive, inappropriate use of next-generation sequencing may waste scarce research funds and other resources. Microarrays presently remain the technology of choice in applications that require fast, cost-effective genome-wide screening of variants of known importance, particularly for large sample sizes. This commentary considers some of the applications where microarrays continue to offer advantages over next-generation sequencing technologies. View Full-Text
Keywords: microarray; next-generation sequencing; pharmacogenomics; personalized healthcare microarray; next-generation sequencing; pharmacogenomics; personalized healthcare
MDPI and ACS Style

Shahandeh, A.; Johnstone, D.M.; Atkins, J.R.; Sontag, J.-M.; Heidari, M.; Daneshi, N.; Freeman-Acquah, E.; Milward, E.A. Advantages of Array-Based Technologies for Pre-Emptive Pharmacogenomics Testing. Microarrays 2016, 5, 12.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop